NATCOPHARM - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 2.8
Show all parameters (20 more)
🧾 Trade Setup
Optimal Buy Price: 815 ₹. Initial Stop Loss: 790 ₹. Target 1: 840 ₹ (based on initial momentum). Target 2: 865 ₹ – contingent upon sustained volume above 5 million shares; if the price breaches 840₹ quickly, consider a tactical exit around 850 ₹ for risk management. Overall, this is a moderately positive setup given today's volume and profit results, but manage the risk carefully due to the high valuation and QoQ profit decline.
✅ Positive
The company reported a strong net profit of ₹151.3 Crore in the last quarter, significantly exceeding expectations and driving substantial volume today. Furthermore, DII holding has increased by 0.17%, suggesting growing investor interest.
⚠️ Limitation
[Corrected] Stock P/E (16.3) is actually LOWER than Industry PE (34.8), a discount to industry peers rather than a premium - treat the valuation framing below with that in mind. Despite the recent profit surge, the QoQ decline in profits (-83.9%) is a significant concern. The stock’s high P/E ratio of 16.3 relative to the industry average (34.8) indicates potential overvaluation and could create vulnerability if momentum stalls.
📉 Company Negative News
The company announced a rights issue, which can sometimes dilute existing shareholders' holdings and negatively impact sentiment, especially if not well-received by the market.
📈 Company Positive News
The reported revenue of ₹705.4 Crore demonstrates continued sales growth and market demand for Natco’s products.
🏭 Industry
The pharmaceutical sector is currently facing increased regulatory scrutiny, which could weigh on investor confidence. However, the industry remains relatively resilient due to ongoing demand for generic drugs.